<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4386">
  <stage>Registered</stage>
  <submitdate>9/12/2013</submitdate>
  <approvaldate>9/12/2013</approvaldate>
  <nctid>NCT02105870</nctid>
  <trial_identification>
    <studytitle>A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function</studytitle>
    <scientifictitle>A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function</scientifictitle>
    <utrn />
    <trialacronym>Intracor</trialacronym>
    <secondaryid>SVH 001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myocardial Infarction</healthcondition>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Abciximab

Experimental: Intracoronary abciximab (Reopro) - Intracoronary abciximab (Reopro)

Placebo Comparator: Control group - Intracoronary Reopro


Treatment: drugs: Abciximab
This drug will be administered intracoronary before percutaneous coronary intervention.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Index of Microvascular Resistance - We will assess IMR in the catheterisation laboratory immediately before PCI, then intracoronary reopro or placebo will be administered and we will re-assess IMR 15 minutes post delivery of the study drug. Finally we will perform PCI and immediately measure IMR post-procedure.</outcome>
      <timepoint>within 3 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of periprocedural myocardial infarction - We will assess for periprocedural myocardial infarction 8 to 24 hours post PCI</outcome>
      <timepoint>within 24 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient with acute coronary syndromes</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient with untreated malignancy, disseminated malignancy, active inflammatory
             diseases, active infectious diseases patients unable to give informed consent Patients
             with STEMI</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>St Vincent's Hospital - Fitzroy</hospital>
    <postcode>3101 - Fitzroy</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Melbourne</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients
      suffering an acute myocardial infarction.

      The investigators hypothesise that treatment with intracoronary abciximab, a potent anti
      platelet agent, at the time of coronary stent insertion, will improve microvascular function.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02105870</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Wilson, MD PhD</name>
      <address>University of Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>